Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Tel Aviv University | OTHER |
| AiCuris Anti-infective Cures AG | INDUSTRY |
| University of Bristol | OTHER |
| UMC Utrecht |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant gram-negative bacteria (COMBACTE-MAGNET,WP5)
Bacterial resistance to antimicrobial drugs is a major public health problem. Of greatest concern is the rapid emergence and dissemination of resistance to third generation cephalosporins in Enterobacteriaceae, especially Escherichia coli and Klebsiella pneumoniae. This is frequently seen in association with resistance to other classes of antibiotics leading to a multidrug resistance (MDR) profile. These MDR isolates are often involved in complicated urinary tract infection (cUTI), and are associated with poor clinical outcomes. In addition, in the last decade there has been an emergence of carbapenemase-producing Enterobacteriaceae, which are also resistant to other antibiotics than carbapenems, leaving few therapeutic options.
The overall aim of this study is to provide information about the epidemiology, clinical management and outcome of patients hospitalised with cUTI, including pyelonephritis. To achieve this aim, the investigators will perform a multicentre retrospective observational study in patients with hospitalised cUTI. The study will be conducted in several European countries plus Israel, which have a high prevalence of MDR Gram-negative bacteria (GNB), including Pseudomonas aeruginosa. The study will seek to identify possible modifiable risk factors for treatment failure, especially those related to antibiotic therapy.
On completion of this study, the investigators will develop a better understanding of the clinical management of hospitalised patients with cUTI due to MDR GNB in European countries. The investigators will identify the modifiable risk factors for treatment failure. This information will be used to inform better clinical and antibiotic management of cUTI to improve patient outcomes. The study will also be used in the development of hypothesis for future randomised controlled trials in cUTI with new antibiotics. Dissemination of results will take place through peer-reviewed publications and conference presentations.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Treatment Failure | Treatment failure will be assessed as number of participants with evidence of treatment failure or mortality within 30 days from initial cUTI diagnosis | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Time to clinical response | Time to clinical response (in days), since initiation of antibiotic treatment | 30 days |
| Time to urological intervention for source control | Time to urological intervention for source control (in days) since initial cUTI diagnosis |
Not provided
Inclusion Criteria:
Patients with UTI and at least one of the following underlying conditions:
and at least one of the following signs or symptoms:
and at least one of the following microbiological results:
Exclusion Criteria:
Not provided
Not provided
Not provided
Hospitalised patients from 1st January 2013 to the 31st December 2014. Diagnosis of cUTI as the primary cause of hospitalisation and patients hospitalised for another reason but who developed cUTI during their hospitalisation. Patients will be identified by searching for any of the following ICD-9 CM or ICD-10 CM codes at discharge on the hospital administration system: ICD-9 CM Codes: 590.1, 590.10, 590.11, 590.2, 590.8, 590.80, 590.9, 595.0, 595.89, 595.9, 99.0 ICD-10 CM Codes: N10, N12, N13.6, N15.1, N15.9, N30.0, N30.8, N30.9, N39.0
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dora Tancheva, Mrs | Emergency Hospital Pirogov, Sofia, Bulgaria | Principal Investigator |
| Rossitza Vatcheva-Dobrevska, Prof | University Hospital Queen Joanna, Sofia, Bulgaria | Principal Investigator |
| Sotirios Tsiodras, Prof | Attikon University Hospital, Athens, Greece | Principal Investigator |
| Emmanuel Roilides, Prof | Hippokration Hospital, Thessaloniki, Greece | Principal Investigator |
| Istvan Vakonyi, MD | Kenezy University Hospital,Debrecen, Hungary | Principal Investigator |
| Aniko Farkas, MD | Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház (SZSZBMK). Nyíregyháza, Hungary | Principal Investigator |
| Leonard Leibovici, Prof | Beilinson Hospital, Rabin Medical Center. Petah-TiqvaI, Israel | Principal Investigator |
| Mical Paul, Prof | Rambam Health Care Campus. Haifa, Israel | Principal Investigator |
| Yehuda Carmeli, Prof | Tel Aviv Medical Center, Tel Aviv. Israel |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Emergency Hospital Pirogov | Sofia | Bulgaria | ||||
| University Hospital Queen Joanna |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24287460 | Background | Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel). 2013 Nov 1;6(11):1335-46. doi: 10.3390/ph6111335. | |
| 22763019 | Background | Hoban DJ, Lascols C, Nicolle LE, Badal R, Bouchillon S, Hackel M, Hawser S. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010. Diagn Microbiol Infect Dis. 2012 Sep;74(1):62-7. doi: 10.1016/j.diagmicrobio.2012.05.024. Epub 2012 Jul 2. |
| Label | URL |
|---|---|
| UK Five Year Antimicrobial Resistance Strategy 2013-2018, September 2013. | View source |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
| 30 days |
| Time to death | Time to death (in days) since original cUTI diagnosis | 30 days |
| Duration of antibiotic therapy | Duration of antibiotic therapy (in days) | 30 days |
| Length of hospital stay | Length of hospital stay (in days) | 30 days |
| Hospital mortality | Hospital mortality during admission | 30 days |
| All cause mortality within 30 days of the original cUTI diagnosis | All cause mortality within 30 days of the original cUTI diagnosis | 30 days |
| All cause of mortality for two months after hospital discharge | All cause of mortality for two months after hospital discharge | 60 days |
| Cost per case of cUTI | Cost per case of cUTI | 30 days |
| Readmissions to the hospital within 60 days of hospital discharge | Readmissions to the hospital within 60 days of hospital discharge | 60 days |
| Adverse events related to antibiotic treatment including: moderate or severe allergic reactions, severe renal impairment, Clostridium difficile infection | Adverse events related to antibiotic treatment including: moderate or severe allergic reactions, severe renal impairment, Clostridium difficile infection | 30 days |
| Principal Investigator |
| Emanuele Durante Mangoni, Prof | AORN dei Colli Monaldi. Napoli, Italy | Principal Investigator |
| Erica Franceschini, MD | Azienda ospedaliero-universitaria policlinico di modena, Modena, Italy | Principal Investigator |
| Nicola Petrosillo, MD | National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy | Principal Investigator |
| Andrei Ursache, MD | "Spitalul Clinic de Urgenta Bucuresti. Popular unoficial name ""Floreasca "" Hospital", Bucharest, Romania | Principal Investigator |
| Judit Bodnár, MD | Soproni Erzsébet Oktató Kórház és Rehabilitációs Intézet, Sopron, Hungary | Principal Investigator |
| Yehuda Carmeli, Prof | Tel Aviv Medical Center, Tel Aviv, Israel | Principal Investigator |
| Andrei Vata, MD | Infectious Diseases Hospital Sfanta Parascheva Iasi, Iasi, Romania | Principal Investigator |
| Adriana Hristea, MD | National Institute for Infectious Diseases Prof Dr Matei Bals, Bucharest, Romania | Principal Investigator |
| Jesus Rodriguez-Bano, Prof | Hospital Universitario Virgen Macarena, Seville, Spain | Principal Investigator |
| Julia Origüen, MD | Hospital Universitario 12 de Octubre, Madrid, Spain | Principal Investigator |
| Arzu Yetkin, MD | Ankara Numune Egitim ve ArastÄrma Hastanesi, Ankara, Turkey | Principal Investigator |
| Nese Saltoglu, Prof | Istanbul University Cerrahpasa Medical School, Istambul, Turkey | Principal Investigator |
| Miquel Pujol, MD | Hospital Universitari de Bellvitge, Barcelona, Spain | Principal Investigator |
| Sofia |
| Bulgaria |
| Attikon University Hospital | Athens | Greece |
| Hippokration Hospital | Thessaloniki | Greece |
| Kenezy University Hospital | Debrecen | Hungary |
| Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház (SZSZBMK) | Nyíregyháza | Hungary |
| Soproni Erzsébet Oktató Kórház és Rehabilitációs Intézet | Sopron | Hungary |
| Rambam Health Care Campus | Haifa | Israel |
| Beilinson Hospital, Rabin Medical Center | Petah Tikva | Israel |
| Tel Aviv Medical Center | Tel Aviv | Israel |
| Azienda Ospedaliero-Universitaria Policlinico Di Modena | Modena | Italy |
| AORN dei Colli Monaldi | Naples | Italy |
| National Institute for Infectious Diseases L. Spallanzani, IRCCS | Rome | Italy |
| "Spitalul Clinic de Urgenta Bucuresti. Popular unoficial name ""Floreasca "" Hospital" | Bucharest | Romania |
| National Institute for Infectious Diseases Prof Dr Matei Bals | Bucharest | Romania |
| Infectious Diseases Hospital Sfanta Parascheva Iasi | Iași | Romania |
| Hospital Universitari de Bellvitge | L'Hospitalet Del Llobregat | Barcelona | 08907 | Spain |
| Hospital Universitario 12 de Octubre | Madrid | Spain |
| Hospital Universitario Virgen Macarena | Seville | Spain |
| Ankara Numune Egitim ve Arastırma Hastanesi | Ankara | Turkey (Türkiye) |
| Istanbul University Cerrahpasa Medical School | Istanbul | Turkey (Türkiye) |
| 21291846 | Background | Yang YS, Ku CH, Lin JC, Shang ST, Chiu CH, Yeh KM, Lin CC, Chang FY. Impact of Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections. J Microbiol Immunol Infect. 2010 Jun;43(3):194-9. doi: 10.1016/S1684-1182(10)60031-X. |
| 24071027 | Background | Ha YE, Kang CI, Cha MK, Park SY, Wi YM, Chung DR, Peck KR, Lee NY, Song JH. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents. 2013 Nov;42(5):403-9. doi: 10.1016/j.ijantimicag.2013.07.018. Epub 2013 Sep 7. |
| 24573013 | Background | Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis. 2014 Apr;27(2):200-10. doi: 10.1097/QCO.0000000000000038. |
| 19696123 | Background | Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Kumar A, Simon D, Peters C, Ahsan M, Chateau D; Cooperative Antimicrobial Therapy of Septic Shock Database Research Group. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009 Nov;136(5):1237-1248. doi: 10.1378/chest.09-0087. Epub 2009 Aug 20. |
| 24158412 | Background | Spoorenberg V, Hulscher ME, Akkermans RP, Prins JM, Geerlings SE. Appropriate antibiotic use for patients with urinary tract infections reduces length of hospital stay. Clin Infect Dis. 2014 Jan;58(2):164-9. doi: 10.1093/cid/cit688. Epub 2013 Oct 24. |
| 23378123 | Background | Levison ME, Kaye D. Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens. Curr Infect Dis Rep. 2013 Apr;15(2):109-15. doi: 10.1007/s11908-013-0315-7. |
| 9098661 | Background | Nicolle LE. A practical guide to the management of complicated urinary tract infection. Drugs. 1997 Apr;53(4):583-92. doi: 10.2165/00003495-199753040-00004. |
| 12113866 | Background | Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002 Jul 8;113 Suppl 1A:5S-13S. doi: 10.1016/s0002-9343(02)01054-9. |
| 3558716 | Background | Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8. |
| Background | Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In Evaluation of chemotherapeutic agents. Edited by MacLeod CM. New York: Columbia University Press; 1949:191-205. |
| 15509405 | Background | Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004 Oct;9(4):197-204. doi: 10.1258/1355819042250249. |
| 21793988 | Background | Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27. |
| 27473949 | Derived | Shaw E, Addy I, Stoddart M, Vank C, Grier S, Wiegand I, Leibovici L, Eliakim-Raz N, Vallejo-Torres L, Morris S, MacGowan A, Carratala J, Pujol M; COMBACTE-MAGNET Consortium. Retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria (RESCUING). BMJ Open. 2016 Jul 29;6(7):e011500. doi: 10.1136/bmjopen-2016-011500. |
| Guidelines on urological infections. European Association of Urology 2014 | View source |
| Complicated Urinary Tract Infections: Developing Drugs for Treatment. Guidance for Industry (2015). U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER). | View source |
| International Classification of Diseases ICD-9 Data. | View source |
| International Statistical Classification of diseases and related Health Problems 10th Revision. ICD-10. Version 2015. | View source |
| University of Maryland Medical Center. Urinary tract Infection | View source |
| Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data | View source |
| ID | Term |
|---|---|
| D014552 | Urinary Tract Infections |
| ID | Term |
|---|---|
| D007239 | Infections |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided